PMID: 6108588Jan 1, 1980Paper

The effects of flurazepam, lorazepam, and triazolam on sleep and memory

Psychopharmacology
T RothM Kramer

Abstract

This study evaluated the effects of flurazepam 30 mg, lorazepam 4 mg, triazolam 0.5 mg, and placebo upon sleep and memory in eleven normal male subjects continuously monitored for nighttime EEG, EOG, and EMG recording. Subjects received each drug or placebo for two consecutive nights per week for 4 weeks in a repeated measures, double-blind, Latin Square design. Three hours post-administration, subjects were awakened and presented with a series of tasks. Recall was assessed immediately following task presentation and after the final morning awakening. The results showed that every drug significantly decreased stage 1, increased stage 2, and produced no change in stage 3--4 sleep in comparison to placebo. Only lorazepam significantly decreased REM percent. Post-drug recall was significantly decreased in comparison to placebo at night and was further decreased in the morning. Morning recall was significantly poorer when the return to sleep was 2.5 min or less than when the return to sleep was greater than 5 min following the nighttime awakening in all drug conditions. These results indicate that 1. failure of memory consolidation rather than failure of retrieval is the most likely explanation for the morning memory loss and 2. hy...Continue Reading

References

Feb 1, 1976·Clinical Pharmacology and Therapeutics·R I WangE Hieb
May 1, 1976·Clinical Pharmacology and Therapeutics·A KalesJ D Kales
Jan 1, 1976·The Journal of International Medical Research·T RothT Lutz
Oct 1, 1977·British Journal of Anaesthesia·J W DundeeK A George
May 1, 1978·Journal of Clinical Pharmacology·M Leibowitz, A Sunshine
Apr 5, 1979·The New England Journal of Medicine·F SolomonW B Mendelson
Jan 1, 1975·Psychopharmacologia·G VogelK Sexton
Jan 1, 1975·British Journal of Anaesthesia·D V Heisterkamp, P J Cohen
Sep 1, 1975·Clinical Pharmacology and Therapeutics·A KalesM B Scharf
Oct 15, 1979·Life Sciences·E O BixlerA Kales
Dec 1, 1973·Journal of Pharmaceutical Sciences·S A KaplanL Weissman
Oct 1, 1971·Anaesthesia·S K PanditS R Keilty
Aug 1, 1970·British Journal of Anaesthesia·P R ClarkeJ A Thornton
Jun 26, 2001·Psychiatry and Clinical Neurosciences·T HoriUNKNOWN Sleep Computing Committee of the Japanese Society of Sleep Research Society

❮ Previous
Next ❯

Citations

Jan 1, 1985·Psychopharmacology·D J Sanger, D Joly
Jan 1, 1982·Psychopharmacology·C L Spinweber, L C Johnson
Jan 1, 1985·Psychopharmacology·D Schneider-Helmert
Jan 1, 1982·Psychopharmacology·L C Johnson, D A Chernik
Jan 1, 1989·Psychopharmacology·S SmirneS R Bareggi
Jan 1, 1992·Psychopharmacology·H J WeingartnerO Wolkowitz
Jan 1, 1991·Psychopharmacology·S R BareggiS Smirne
Aug 1, 1985·Accident; Analysis and Prevention·T Roth, T Roehrs
Mar 1, 1984·Electroencephalography and Clinical Neurophysiology·G D Novack, K M Owenburg
Feb 1, 1984·Pharmacology, Biochemistry, and Behavior·R I Block, R Berchou
Apr 6, 1991·Lancet·E O BixlerJ D Kales
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·R G Lister
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·R R GriffithsJ V Brady
Jan 1, 1986·Progress in Neuro-psychopharmacology & Biological Psychiatry·T SunderlandR M Cohen
Jan 1, 1992·Progress in Neuro-psychopharmacology & Biological Psychiatry·M TaftiM Billiard
May 1, 1993·Progress in Neuro-psychopharmacology & Biological Psychiatry·I HindmarchJ S Kerr
Mar 1, 1993·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J RöschkeJ B Aldenhoff
Jul 29, 1998·Psychiatry and Clinical Neurosciences·K MisakiT Ito
Aug 18, 1983·The New England Journal of Medicine·D J GreenblattD R Abernethy
Aug 27, 2005·The New England Journal of Medicine·Michael H Silber
May 7, 2004·Neuroreport·Karen A MaubachGuy R Seabrook
Dec 1, 1982·Journal of Pharmacological Methods·S BanfiL Dorigotti
Feb 11, 2005·Current Medical Research and Opinion·Gary K ZammitThomas Roth
Dec 29, 2006·Pharmacotherapy·Anna K MorinAnn M Lynch
Mar 1, 1989·The Journal of Emergency Medicine·J S Huff, H G Plunkett
Jan 1, 1983·British Journal of Clinical Pharmacology·G W Vogel, F Vogel
Jan 1, 1983·Psychophysiology·M H Bonnet
Jan 1, 1988·Journal of Clinical Pharmacology·D J McClureJ C Pecknold
Jan 1, 1984·British Journal of Clinical Pharmacology·T RothF Zorick
Jan 18, 2003·Sleep Medicine Reviews·Shawn D. Youngstedt
Nov 1, 1993·The Journal of the American Dental Association·C W BertholdR A Dionne
Sep 25, 2003·Sleep Medicine Reviews·Shawn D Youngstedt
Jun 1, 1991·The American Journal of Drug and Alcohol Abuse·R M AnthenelliM A Schuckit

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.